Ursodiol
Ursodiol (Ursodeoxycholic acid) is bile acids used in treatment of primary biliary cirrhomized (PBC) [1].
Ursodiol (Ursodeoxycholic acid) has been reported to prevent progression of PBC, and increase survival. In addition, Ursodiol has been revealed to inhibit the initiation and postinitiation phases of azoxymethane-induced colonic tumor development. Moreover, Ursodiol has been noted to dose-dependently inhibit the viability of HepG2 and BEL7402 cell lines with IC50 values of 0.92mmol/L and 0.86mmol/L, respectively. Ursodiol has also reported to dose-dependently and significantly enhance the apoptosis rates in HepG2 and BEL7402 cells. Besides, treatment of Ursodiol has shown the reduction of the ecpression of cell cycle regulating proteins (cyclinD1,cyclin D3, Cdk2 and Cdk4) in Western blot analysis [1].
References:
[1] Liu H1, Qin CY, Han GQ, Xu HW, Meng M, Yang Z. Mechanism of apoptotic effects induced selectively by ursodeoxycholic acid on human hepatoma cell lines. World J Gastroenterol. 2007 Mar 21;13(11):1652-8.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 392.57 |
| Cas No. | 128-13-2 |
| Formula | C24H40O4 |
| Solubility | insoluble in H2O; ≥16 mg/mL in DMSO; ≥50.5 mg/mL in EtOH |
| Chemical Name | (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid |
| SDF | Download SDF |
| Canonical SMILES | O[C@H]1C[C@](C[C@H](O)[C@]2([H])[C@]3([H])CC[C@@]4(C)[C@@]2([H])CC[C@]4([H])[C@H](C)CCC(O)=O)([H])[C@]3(C)CC1 |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
Quality Control & MSDS
- View current batch:
Chemical structure
